U.S. Markets closed

Curis, Inc. (CRIS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.25+0.26 (+2.60%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.99
Open10.09
Bid10.00 x 1400
Ask10.49 x 1000
Day's Range9.98 - 10.29
52 Week Range0.62 - 13.44
Volume1,040,456
Avg. Volume2,139,353
Market Cap938.071M
Beta (5Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)-0.62
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.20
  • Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
    PR Newswire

    Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2021 financial results on Wednesday, May 12, 2021, after the close of US markets. Management will host a conference call on the same day at 4:30 pm ET.

  • Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know

    Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
    PR Newswire

    Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for CA-4948, a first-in-class, small molecule inhibitor of IRAK4 and Curis's most advanced therapeutic in clinical development. CA-4948 targets IRAK4-L, the oncogenic isoform of IRAK4 preferentially expressed by the majority of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and has shown broad clinical activity in Phase 1 trials in patients with relapsed or refractory (R/R) AML/MDS.